In the current pilot study we aimed to identify differentially expressed miRNAs in two types of single hormone receptor-positive breast cancers (ER(+)/PgR(−) and ER(−)/PgR(+)) with further distinction into HER2-overexpressing/amplified and HER2-negative tumors in a well-established cohort collected at the Medical University of Gdańsk. The gene discussed is ESR1; the disease is breast carcinoma.